Chemoinformaics analysis of 1,4,7,10,13,16-Hexaoxacyclooctadecane
| Molecular Weight | 264.318 | nRot | 0 |
| Heavy Atom Molecular Weight | 240.126 | nRig | 18 |
| Exact Molecular Weight | 264.157 | nRing | 1 |
| Solubility: LogS | 0.474 | nHRing | 1 |
| Solubility: LogP | -0.446 | No. of Aliphatic Rings | 1 |
| Acid Count | 0 | No. of Aromatic Rings | 0 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 0 |
| Atoms Count | 42 | No. of Aliphatic Hetero Cycles | 1 |
| No. of Heavy Atom | 18 | No. of Aromatic Carbocycles | 0 |
| nHetero | 6 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 24 | No. of Saturated Hetero Cycles | 1 |
| No. of Carbon atom | 12 | No. of Saturated Rings | 1 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 0 |
| No. of Oxygen atom | 6 | No. of Arom Bond | 0 |
| nHA | 6 | APOL | 40.855 |
| nHD | 0 | BPOL | 34.493 |
| QED | 0.618 |
| Synth | 2.175 |
| Natural Product Likeliness | -0.272 |
| NR-PPAR-gamma | 0.038 |
| Lipinski | Accepted |
| Pfizer | Accepted |
| GSK | Accepted |
| Golden Triangle | Accepted |
| Pgp-inh | 0.005 |
| Pgp-sub | 0.002 |
| HIA | 0.002 |
| CACO-2 | -4.618 |
| MDCK | 0.0000222 |
| BBB | 0.056 |
| PPB | 0.151698 |
| VDSS | 0.578 |
| FU | 0.469035 |
| CYP1A2-inh | 0.004 |
| CYP1A2-sub | 0.077 |
| CYP2c19-inh | 0.014 |
| CYP2c19-sub | 0.059 |
| CYP2c9-inh | 0.001 |
| CYP2c9-sub | 0.004 |
| CYP2d6-inh | 0.003 |
| CYP2d6-sub | 0.027 |
| CYP3a4-inh | 0.004 |
| CYP3a4-sub | 0.14 |
| CL | 3.107 |
| T12 | 0.501 |
| hERG | 0.985 |
| Ames | 0.062 |
| ROA | 0.028 |
| SkinSen | 0.933 |
| Carcinogencity | 0.601 |
| EI | 0.991 |
| Respiratory | 0.004 |
| NR-Aromatase | 0.768 |
| Antiviral | Yes |
| Prediction | 0.669945 |